Transcatheter Aortic Valve Replacement for Left Ventricular Assist Device–Related Aortic Regurgitation: The Michigan Medicine Experience

Aortic regurgitation (AR) is common and detrimental in patients with left ventricular assist devices (LVADs). Off-label use of transcatheter aortic valve replacement (TAVR) has emerged as a potential treatment option. Further data are required regarding the feasibility and outcomes of TAVR to treat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Society for Cardiovascular Angiography & Interventions 2023-01, Vol.2 (1), p.100530, Article 100530
Hauptverfasser: Gondi, Keerthi T., Tam, Marty C., Chetcuti, Stanley J., Pagani, Francis D., Grossman, P. Michael, Deeb, G. Michael, Menees, Daniel P., Haft, Jonathan W., Patel, Himanshu J., Aaronson, Keith D., Sukul, Devraj
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aortic regurgitation (AR) is common and detrimental in patients with left ventricular assist devices (LVADs). Off-label use of transcatheter aortic valve replacement (TAVR) has emerged as a potential treatment option. Further data are required regarding the feasibility and outcomes of TAVR to treat AR in LVAD recipients. A retrospective review of all patients with LVADs who underwent TAVR for the treatment of AR at a single center was performed. All echocardiograms were independently reviewed to ensure accuracy. Eleven patients with continuous-flow LVADs underwent TAVR for AR. All patients had moderate or severe AR with New York Heart Association (NYHA) class III and IV symptoms. Implantation of more than 1 valve was required in 4 (36.3%) patients; 1 patient died during the procedure because of valve migration into the left ventricle and 1 patient died in-hospital after TAVR. Of 9 (81.8%) patients discharged alive, 8 (72.7%) were alive at 12 months and all survivors had improvement in AR severity, natriuretic peptide levels, left ventricle end-diastolic diameter, and NYHA class. Five (62.5%) survivors had a large improvement (>20 points) in the Kansas City Cardiomyopathy Questionnaire score at 1 year. One survivor experienced heart failure, requiring hospitalization, within 1 year. In this single-center series, TAVR for the treatment of AR in patients with LVADs is technically challenging but feasible in select patients and may produce durable improvements in AR severity, functional status, and quality of life. [Display omitted] •Transcatheter aortic valve replacement for the off-label treatment of left ventricular assist device–related aortic regurgitation is technically challenging.•Patients with left ventricular assist devices are at a particularly high risk of device migration during transcatheter aortic valve replacement.•Meticulous preprocedure planning is critical to facilitate technical success.•Transcatheter aortic valve replacement resulted in clinical improvement in carefully selected patients with left ventricular assist devices.
ISSN:2772-9303
2772-9303
DOI:10.1016/j.jscai.2022.100530